

STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

TRIENTINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TRIENTINE HCL	SYPRINE,	01109		GPI-10	
	CLOVIQUE			(9920002010)	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

- 1. Does the patient have a diagnosis of Wilson's disease and meet **ALL** of the following criteria?
 - Therapy is prescribed by or in consultation with a hepatologist or gastroenterologist
 - The patient has a Leipzig score of 4 or greater
 - The patient is willing to follow a diet avoiding high copper foods (e.g., shellfish, nuts, chocolate, mushrooms, organ meat)
 - The patient has had a trial of or contraindication to penicillamine (Depen, Cuprimine)

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #8 per day. If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **TRIENTINE** (Syprine, Clovique) requires the following rule(s) be met for approval:

- A. You have Wilson's disease (a genetic disorder that leads to copper accumulation in the organs)
- B. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor) or gastroenterologist (a type of digestive system doctor)
- C. You have a Leipzig score (a type of diagnostic score) of 4 or higher
- D. You are willing to follow a diet avoiding high copper foods (such as shellfish, nuts, chocolate, mushrooms, organ meat)
- E. You had a trial of or contraindication (harmful for) to penicillamine (Depen, Cuprimine)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 4/21/2023 Page 1 of 2



STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

TRIENTINE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- 1. Does the patient have a diagnosis of Wilson's disease AND meet the following criterion?
 - The patient has achieved a free serum copper of less than 10 mcg/dL

If yes, approve for lifetime by HICL or GPI-10 with a quantity limit of #8 per day. If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **TRIENTINE** (Syprine, Clovique) requires the following rules be met for renewal:

- A. You have Wilson's disease (a genetic disorder that leads to copper accumulation in the organs)
- B. You have achieved a free serum copper (amount of copper in your blood) level of less than 10 mcg/dL

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Syprine.

REFERENCES

- Syprine [Prescribing Information]. Bridgewater, NJ: Bausch Health Companies Inc.; September 2020.
- Clovique [Prescribing Information]. Warrendale, PA: Kadmon Pharmaceuticals, LLC; September 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A Created: 08/16

Commercial Effective: 05/08/23 Client Approval: 04/23 P&T Approval: 10/22

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 4/21/2023 Page 2 of 2